) J. Neurosci. 26, 11599 -11605) azietomidate photolabeling of GABA A R ␣1Met-236 and Met-286 (in ␣M1 and M3). Positioning these two photolabeled amino acids in a single type of binding site at the interface of  and ␣ subunits (two copies per pentamer) is consistent with a GABA A R homology model based upon the structure of the nicotinic acetylcholine receptor and with recent ␣M1 to M3 cross-linking data. Biologically active neurosteroids enhance rather than inhibit azietomidate photolabeling, as assayed at the level of GABA A R subunits on analytical SDS-PAGE, and protein microsequencing establishes that the GABA A R-modulating neurosteroids do not inhibit photolabeling of GABA A R ␣1Met-236 or Met-286 but enhance labeling of ␣1Met-236. Thus modulatory steroids do not bind at the same site as etomidate, and neither of the amino acids identified as neurosteroid activation determinants (Hosie, A. M., Wilkins, M. E., da Silva, H. M., and Smart, T. G. (2006) Nature 444, 486 -489) are located at the subunit interface defined by our etomidate site model.
GABA A3 receptors (GABA A R) are major mediators of brain inhibitory neurotransmission and participate in most circuits and behavioral pathways relevant to normal and pathological function (1). GABA A R are subject to modulation by endogenous neurosteroids, as well as myriad clinically important central nervous system drugs including general anesthetics, benzodiazepines, and possibly ethanol (1, 2). The mechanism of GABA A R modulation by these different classes of drugs is of major interest, including identification of the receptor amino acid residues involved in binding and action of the drugs.In the absence of high resolution crystal structures of drugreceptor complexes, the locations of anesthetic binding sites in GABA A Rs have been predicted based upon analyses of functional properties of point mutant receptors, which identified residues in the ␣ and  subunit M1-M4 transmembrane helices important for modulation by volatile anesthetics (primarily ␣ subunit) and by intravenous agents, including etomidate and propofol ( subunit) (3-5). Position M2-15, numbered relative to the N terminus of the helix, functions as a major determinant of etomidate and propofol potency as GABA modulators in vitro and in vivo (6 -8). By contrast, this residue is not implicated for modulation by the neurosteroids, potent endogenous modulators of GABA A R (9).Photoaffinity labeling, which allows the identification of residues in proximity to drug binding sites (10, 11), has been used to identify two GABA A R amino acids covalently modified by the etomidate analog [ 3 H]azietomidate (12): ␣1Met-236 within ␣M1 and Met-286 within M3. Photolabeling of these residues was inhibited equally by nonradioactive etomidate and enhanced proportionately by GABA present in the assay, consistent with the presence of these two residues in a common drug binding pocket that would be located at the interface between the  and ␣ subunits in the transmembrane domain (12). Mutational analyses identi...